Caladrius Biosciences, Inc. (NASDAQ: CLBS) Starts Presentation at LD Micro 2017 Invitational
Caladrius Biosciences (NASDAQ: CLBS) is advancing a proprietary platform technology for immunomodulation by pioneering the use of T regulatory cells as an innovative therapy for recent onset Type 1 diabetes. Product candidate CLBS03 is the subject of an ongoing phase 2 clinical trial (The Sanford Project: T-Rex study) in collaboration with Sanford Research, and has been granted Orphan Drug and Fast Track designation by the U.S. Food and Drug Administration, as well as Advanced Therapeutic Medicinal Product classification by the European Medicines Agency. The company’s subsidiary, PCT, is a well-known development and manufacturing partner exclusively focused on the cell therapy…